184 related articles for article (PubMed ID: 32700765)
1. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
Yi ZB; Yu P; Zhang S; Wang WN; Han YQ; Ouyang QC; Yan M; Wang XJ; Hu XC; Jiang ZF; Huang T; Tong ZS; Wang SS; Yin YM; Li H; Yang RX; Yang HW; Teng YE; Sun T; Cai L; Li HY; Chen X; He JJ; Liu XL; Yang SE; Wang JY; Fan JH; Qiao YL; Xu BH
Int J Cancer; 2021 Feb; 148(3):692-701. PubMed ID: 32700765
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
5. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
Shen J; Xu L; Shi J; Zhao L; Shi S; Feng J; Han X; Shi Y; Wei Q; Wang D; Sun M; Mi X; Teng Y
Oncol Res Treat; 2020; 43(11):620-627. PubMed ID: 32966998
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
8. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
[No Abstract] [Full Text] [Related]
9. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
[No Abstract] [Full Text] [Related]
10. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
11. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
12. Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis.
Mellouli M; Graja S; Kridis WB; Ayed HB; Makni S; Triki M; Charfi S; Khanfir A; Boudawara TS; Kallel R
Ann Diagn Pathol; 2022 Dec; 61():152044. PubMed ID: 36099874
[TBL] [Abstract][Full Text] [Related]
13. Receptor conversion in distant breast cancer metastases.
Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
[TBL] [Abstract][Full Text] [Related]
14. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
16. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
17. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
[TBL] [Abstract][Full Text] [Related]
20. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
